Last updated: May 20, 2026
Cidofovir remains a niche antiviral with constrained commercial scale, driven by its established role in cytomegalovirus (CMV) retinitis in people with AIDS and by limited new development activity. The drug’s commercial trajectory is dominated by (1) aging patient cohorts, (2) competitive dynamics from other antivirals used in CMV disease/retinitis, and (3) high-cost inpatient infusion workflows and monitoring requirements. Market growth is capped by the absence of broad new indications and by the limited number of modern combination regimens that preserve cidofovir as a backbone.
The clinical trial and market outlook below focuses on cidofovir’s current development footing and the practical levers that determine near- to mid-term demand.
What clinical trials are still active for cidofovir in 2026?
Featured-snippet answer: As of current public records, cidofovir’s development footprint is small, with no widely reported, late-stage (Phase 3) registrational programs for new indications. Most incremental activity is driven by post-approval use, investigator-led studies, alternative formulations, or combination exploration rather than full-scale phase programs.
Which trial phases and endpoints have dominated cidofovir research?
Cidofovir historically advanced in the context of CMV disease, with endpoints tied to:
- Ocular progression in CMV retinitis
- Viral load reduction and clinical response in CMV infection
- Safety in immunocompromised populations, with attention to nephrotoxicity
What are the main safety endpoints in current cidofovir studies?
Cidofovir’s development and re-use are constrained by renal toxicity risk and clinical practice monitoring, so trials and real-world protocols typically track:
- Creatinine clearance changes
- Proteinuria and laboratory markers of proximal tubule dysfunction
- Infusion-related adverse events
- Use of renal protective co-therapies (where applicable in protocols)
Is cidofovir being studied for non-CMV indications?
Public development for non-CMV indications is sporadic and typically does not reach large late-stage enrollment. Any signal in rare viral or resistant indications tends to remain small or investigator-led.
What is the latest cidofovir clinical trial status, by indication?
Featured-snippet answer: The most persistent indication link for cidofovir is CMV retinitis in advanced HIV disease. Other viral targets have periodic scientific interest, but they have not translated into a sustained pipeline comparable to mainstream antivirals.
CMV retinitis in HIV/AIDS
Cidofovir’s clinical evidence base is anchored in CMV retinitis. Trial activity historically emphasized:
- Time to retinal disease progression
- Visual outcomes and ocular inflammation measures
- Treatment durability and relapse patterns
- Renal safety and dosing feasibility in immunocompromised settings
CMV disease outside retinitis
Cidofovir use in broader CMV disease settings is limited by renal risk and by the market’s preference for other antivirals with more favorable safety or administration profiles. Trial narratives are usually feasibility, salvage, or resistant-virus niches.
Other viral targets (intermittent exploration)
Scientifically, cidofovir is a nucleoside analog with broad antiviral mechanistic interest. Commercially and clinically, the development emphasis remains modest, and public trial footprints tend to be smaller.
How strong is cidofovir’s patent estate and what risks exist for generic entry?
Featured-snippet answer: Patent/IP risk is not the primary driver for cidofovir’s current commercial scale. The product is long-established, and the market is largely shaped by supply, substitution, and the clinical workflow costs created by dosing and renal monitoring.
What patents historically protected cidofovir?
Cidofovir’s original IP largely covered:
- The active entity
- Specific pharmaceutical formulations and dosing practices
- Use-related claims for CMV indications
Given the drug’s age, much of the early exclusivity has already lapsed, and the dominant “barriers” are clinical, not legal.
What would a generic launch change commercially?
A generic launch primarily matters if it:
- Secures pricing and formulary access
- Preserves supply reliability
- Aligns with current administration and monitoring expectations
For an older specialty antiviral, pricing power is constrained by competing therapeutics and by provider risk tolerance around nephrotoxicity.
What is the Orange Book status of cidofovir and how many ANDAs exist?
Featured-snippet answer: Cidofovir’s FDA status is tied to an approved NDA and any listed generics/alternates reflected in the Orange Book. The commercial reality depends on whether multiple suppliers hold approval and whether they maintain consistent availability.
How Orange Book listings affect real-world supply
For older specialty injectables:
- A limited number of suppliers can create availability volatility
- Contract pricing and hospital procurement cycles determine usable demand
- Renal monitoring burden is the dominant utilization limiter, not formulation availability
(This section is constrained by the absence of the drug-specific Orange Book listing dataset in the prompt. A complete tabulation of NDA/ANDA numbers, listed patents, and expiration dates cannot be produced accurately here.)
When does cidofovir lose exclusivity, and what does that mean for competition?
Featured-snippet answer: Cidofovir is past the main exclusivity window for the originator. Near-term competitive behavior is therefore driven by generic/authorized supply economics and clinical preference rather than by upcoming exclusivity cliffs.
What determines timing of price erosion
Even after exclusivity ends:
- Entry timing depends on manufacturing readiness and regulatory approval
- Tender cycles can slow price drops
- Substitution depends on clinician acceptance and institutional protocols
What formulation and delivery system patents protect cidofovir dosing and renal protection?
Featured-snippet answer: Modern differentiation in cidofovir’s use has less to do with new delivery systems and more to do with dosing regimens and renal protective practices that reduce nephrotoxicity risk.
What formulation attributes matter commercially?
For infused antivirals:
- Stability and shelf life
- Handling characteristics at oncology or infusion centers
- Compatibility with institutional IV workflows
What do renal-protection practices change in demand?
Renal-protection protocols can:
- Increase administration complexity
- Raise monitoring frequency
- Reduce eligible patient throughput
These factors often constrain demand more than any incremental safety improvement.
How does cidofovir compare with valganciclovir, ganciclovir, foscarnet, and letermovir in CMV use?
Featured-snippet answer: Market use of CMV therapeutics generally favors agents with more convenient dosing and more favorable monitoring profiles. Cidofovir is typically positioned as salvage or niche use where alternatives are limited by resistance, intolerance, or specific clinical scenarios.
Comparison drivers that shape prescribing
- Administration: infusion burden for cidofovir versus oral options for valganciclovir
- Safety: renal toxicity and monitoring burden for cidofovir versus alternative renal profiles
- Use-case fit: retinitis salvage niches where cidofovir historical evidence is most relevant
- Drug interaction profile and dosing practicality in immunocompromised settings
Commercial implication
Cidofovir demand is typically less about general CMV incidence growth and more about:
- Rates of salvage use
- Institutional protocols
- Supply and pricing of competing CMV antivirals
What cidofovir clinical outcomes matter for market adoption?
Featured-snippet answer: Adoption hinges on measurable control of CMV retinitis progression and an acceptable renal safety profile under real-world dosing and monitoring constraints.
Outcome categories used in provider decision-making
- Retinal disease stabilization vs progression
- Visual function outcomes and time to relapse
- Nephrotoxicity incidence and reversibility
- Feasibility of delivering full planned dosing in practice
The bottleneck: monitoring and tolerability
Even when efficacy is accepted:
- Creatinine monitoring and renal protective strategies can limit repeat dosing
- Treatment discontinuation risk can shorten utilization cycles
- Provider comfort declines when alternative options are available
What biosimilar or biologics risk exists for cidofovir?
Featured-snippet answer: Biosimilar risk is not applicable because cidofovir is a small-molecule drug, not a biologic.
What patent litigation or Paragraph IV challenges affect cidofovir?
Featured-snippet answer: There is no consistent, widely reported, current litigation narrative for cidofovir that would be expected to materially affect near-term commercial supply. Any litigation would be product- and supplier-specific and typically would surface in Paragraph IV notices or court dockets.
(This section cannot be populated with an accurate case list without a litigation docket dataset or specific notice identifiers.)
Market analysis: How big is cidofovir’s addressable market and why is growth limited?
Featured-snippet answer: Cidofovir’s addressable market is limited by patient population size (historically advanced HIV/AIDS with CMV retinitis), the availability of alternative CMV therapeutics, and the renal monitoring burden that reduces eligible utilization.
Demand drivers
- Patient pool: advanced immunocompromised cohorts
- Salvage/alternative gaps: resistant CMV or intolerance scenarios
- Provider protocols: retinal disease management pathways
- Supply and pricing: availability from generics and distributors
Demand constraints
- Nephrotoxicity and monitoring intensity
- Shift toward other CMV agents with more convenient regimens
- Limited pipeline expansion into new indications
- Institutional risk tolerance and formulary placement
Competitive landscape
- CMV-focused antivirals (systemic and oral) compete for the “first-line” position
- Cidofovir competes mainly in niche roles: salvage and selected retinitis scenarios
Commercial projection for cidofovir (base case, 3-year and 5-year)
Featured-snippet answer: The base case is modest-to-flat growth with episodic volatility driven by supply and institution-level formulary decisions. Sustained CAGR is unlikely without a major indication expansion or a step-change in safety/administration.
Base case (3 years): low-single-digit growth
- Growth is mainly substitution-driven within niche CMV salvage settings.
- Any demand increases are constrained by renal monitoring and by competing antiviral availability.
Downside case: demand compression
- Further formulary restrictions and protocol tightening reduce utilization.
- Pricing pressure from generic competition can lower revenue even if units stabilize.
Upside case: protocol-led rebound
- Short-term utilization rebound could occur if salvage usage increases due to resistance patterns or intolerance to competitors.
- Upside requires measurable clinical adoption, not just theoretical mechanism interest.
What to watch (leading indicators)
- Hospital formulary changes for CMV salvage protocols
- Generic supply continuity
- Any new investigator-led trials that translate into protocol updates
- Shifts in HIV treatment era epidemiology for late-stage CMV retinitis cases
(A quantified revenue forecast and market size in USD requires source-specific inputs not provided in the prompt, so no numeric projection is produced.)
Key takeaways
- Cidofovir’s clinical development activity is limited; the most durable clinical positioning remains CMV retinitis in advanced immunocompromise.
- The market is constrained by renal toxicity risk and monitoring workflow costs, which limit repeat dosing and patient eligibility.
- Commercial growth is likely to be flat to modest, driven by niche salvage use and supply economics rather than by a broad pipeline expansion.
- Competitive pressure comes from CMV antivirals with more convenient administration and/or more favorable practical safety profiles.
FAQs
- Is cidofovir still used for CMV retinitis in current HIV treatment practice?
- What renal monitoring protocols determine whether a patient can receive cidofovir full dosing?
- How do generic cidofovir supply and pricing affect hospital formulary placement?
- What alternative antivirals are typically used before switching to cidofovir in salvage cases?
- Are there any formulation changes or dosing regimens that materially reduce cidofovir nephrotoxicity?
References (APA)
- U.S. Food and Drug Administration. (n.d.). Drug trials snapshots and related regulatory information for cidofovir. https://www.fda.gov
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (cidofovir listings). https://www.accessdata.fda.gov/scripts/cder/daf/
(No additional sources were cited because the prompt did not provide drug-specific trial, Orange Book, or litigation identifiers needed for precise, auditable reporting.)
